Executive Director Wang Yuxiao reduced his holdings in REMEGEN (09995) by 13,500 shares, at a price of approximately HK$81.54 per share.
On August 27, executive director Wang Yuxiao reduced his holdings in Rongchang Biotech (09995) by 13,500 shares, at a price of HKD 81.5352 per share, for a total amount of approximately HKD 1.1007 million.
The latest information from the Hong Kong Stock Exchange shows that on August 27, Executive Director Wang Yuxiao reduced his holdings in REMEGEN (09995) by 13,500 shares, at a price of HKD 81.5352 per share, for a total amount of approximately HKD 1.1007 million. After the reduction, the latest number of shares held is 22.2786 million, with a latest shareholding ratio of 10.68%.
Related Articles
How to choose AI applications in Hong Kong stocks? DIAGENS-B (02526): A rare vertical AI target with high growth and strong barriers.
Valuation at $2 trillion! Anthropic may become the largest IPO in history, starting its roadshow in October and going public before the mid-term elections in November.
Astrazeneca PLC Sponsored ADR (AZN.US) has received accelerated approval from the FDA for a new breast cancer drug, and Wall Street estimates that sales could reach $2.3 billion by 2032.
How to choose AI applications in Hong Kong stocks? DIAGENS-B (02526): A rare vertical AI target with high growth and strong barriers.
Valuation at $2 trillion! Anthropic may become the largest IPO in history, starting its roadshow in October and going public before the mid-term elections in November.
Astrazeneca PLC Sponsored ADR (AZN.US) has received accelerated approval from the FDA for a new breast cancer drug, and Wall Street estimates that sales could reach $2.3 billion by 2032.
RECOMMEND
